Organigram Global Inc.

As of June 30, 2026, Organigram Global Inc. carries a market capitalization of 126.88M, placing it among publicly traded companies globally. Its enterprise value stands at 139.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Organigram Global Inc.'s next confirmed earnings release is scheduled for December 22, 2026.

As of June 30, 2026, Organigram Global Inc. has 140.98M shares outstanding.

As of June 30, 2026, Organigram Global Inc. trades at a trailing price-to-earnings ratio of 2.26. The price-to-sales ratio is 0.63, and the price-to-book ratio stands at 0.42.

As of June 30, 2026, Organigram Global Inc. trades at an EV/EBITDA multiple of 17.89 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.73 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 139.08M versus a market cap of 126.88M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Organigram Global Inc. maintains a current ratio of 2.61, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Organigram Global Inc. posted a return on equity (ROE) of 19.89, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 12.51, measuring how efficiently the asset base is converted into earnings. The company generates approximately 167,413.67 in revenue per employee across its workforce of 1,139.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.35 indicates how many times Organigram Global Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Organigram Global Inc. recorded an income tax benefit of -3.30M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 50.12M, leaving 53.42M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Organigram Global Inc.'s stock has declined approximately 43.26% over the past 52 weeks. The 50-day moving average sits at 0.94, while the 200-day moving average is 1.05.

Over the twelve months ended June 30, 2026, Organigram Global Inc. generated 190.68M in revenue and converted that into 53.42M in net income, yielding earnings per share of 0.40. EBITDA reached 7.77M, while operating income came in at -4.13M.

As of June 30, 2026, Organigram Global Inc. holds 7.20M in cash and equivalents against 19.40M in total debt, resulting in a net debt position of 4.17M. Total book value stands at 299.41M, with working capital of 106.58M providing operational flexibility.

Organigram Global Inc. produced -17.59M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -711,731.32 in capital expenditures, free cash flow totaled -18.30M - equivalent to -0.14 per share.

Over the twelve months ended June 30, 2026, Organigram Global Inc. posted a gross margin of 36.54, reflecting its pricing power and cost economics. The operating margin of -2.16 and net profit margin of 28.02 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.09: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -40.67, meaning Organigram Global Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Organigram Global Inc.'s most recent stock split took place on July 7, 2023 with a 4:1 split ratio.

As of June 30, 2026, Organigram Global Inc. has an Altman Z-Score of -0.07, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.